A number of 2-(1-naphthylmethyl)-2-imidazoline, 2-[1-(1-naphthylethyl]-2-imidazoline, phosphorothioates, and related compounds were prepared for an evaluation as radioprotective agents against γ -rays. In this work, we report the synthesis and evaluation in vivo (radioprotective efficacy and toxicity) of new phosphorothioates. All these derivatives have shown a dose reduction factor between 1.5 and 1.9, which traduces their excellent radioprotective activity. These compounds should present an interest in chimio-and radiotherapy treatments.